1 Mar 2022
Afferent Medical Solutions proudly unveils the receipt of a prestigious £650k RAIA award to run a Phase II clinical trial, focused on exploring the efficacy of TanX (Transcutaneous Autonomic Neuromodulation) in post-stroke recovery patients. This award will not only propel the research and development of tAN but will also facilitate the conceptualisation and subsequent development of a remote patient monitoring solution to complement the existing medical device treatment
Afferent Medical Solutions proudly unveils the receipt of a prestigious £650k RAIA award to run a Phase II clinical trial, focused on exploring the efficacy of TanX (Transcutaneous Autonomic Neuromodulation) in post-stroke recovery patients. This award will not only propel the research and development of tAN but will also facilitate the conceptualisation and subsequent development of a remote patient monitoring solution to complement the existing medical device treatment